Individualized Treatments for HER2-Positive Breast Cancer Investigated

Individualized Treatments for HER2-Positive Breast Cancer Investigated
shutterstock_145005193A number of treatment options are targeted at HER2-positive breast cancer, including carboplatin, anthacycline, and pertuzumab. Although this multitude of options has enhanced breast cancer outcomes for both early-stage and advanced-stage patients, overtreatment is a concern. A means to determine individualized, optimal risk/benefit ratios of treatments for patients is necessary in order to fully utilize the treatments available for breast cancer. According to "HER2-Positive Breast Cancer, Intrinsic Subtypes, and Tailoring Therapy," published in JNCI Journal of the National Cancer Insitute, pathological stage is commonly used to guide clinicians' choice of treatment for their patients. For example, pertuzumab, a HER2 dimerization inhibitor, is recommended for patients with pathological stage III disease, as patients with stage I/IIA, HER2-positive breast cancers are effectively treated with 12 weeks of weekly paclitaxel and a year of trastuzumab. This approach is preferred, as paclitaxel with trastuzumab i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.